{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T23:03:18Z","timestamp":1784156598528,"version":"3.55.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Sunitinib is approved for the treatment of metastatic renal cell carcinoma (mRCC), imatinib-resistant gastrointestinal stromal tumors (GIST), and advanced pancreatic neuroendocrine tumors (PNET). This study aims to investigate the safety profiles of sunitinib through data mining of the US Food and Drug Administration Adverse Event Reporting System (FAERS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The individual case safety reports (ICSRs) on sunitinib from 2006 Q1 to 2024 Q1 were collected from the ASCII data packages in the Food and Drug Administration Adverse Event Reporting System (FAERS). After standardizing the data, a variety of disproportionality analyses, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the bayesian confidence propagation neural network (BCPNN), and the multi-item gamma Poisson shrinker (MGPS) were employed to identify the potential safety signals of sunitinib-associated AEs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 35,923 ICSRs of sunitinib as the \u201cprimary suspected\u201d drug were identified within the reporting period. The search detected 276 disproportionate preferred terms (PTs). The most common AEs, including diarrhea, asthenia, decreased appetite, hypertension, and dysgeusia, were consistent with the drug label and clinical trials. Unexpected significant AEs, such as uveal melanocytic proliferation, salivary gland fistula, yellow skin, eyelash discoloration, scrotal inflammation, were detected. The median onset time of sunitinib-related AEs was 57 days (interquartile range [IQR]16\u2013170 days), with most of the ICSRs developing within the first month (n = 4,582, 39.73%) after sunitinib therapy as initiated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The results of our study were consistent with routine clinical observations, and some unexpected AEs signals were also identified for sunitinib, providing valuable evidence for the safe use of sunitinib in the real-world and contributing to the clinical monitoring and risk identification of sunitinib.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1407709","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T05:09:32Z","timestamp":1721797772000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib"],"prefix":"10.3389","volume":"15","author":[{"given":"Xusheng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanjin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengwu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuicui","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1021\/acs.chemrestox.8b00005","article-title":"Cytochromes P450 1A2 and 3A4 catalyze the metabolic activation of sunitinib","volume":"31","author":"Amaya","year":"2018","journal-title":"Chem. Res. Toxicol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1159\/000511249","article-title":"Sunitinib-induced acute liver failure","volume":"15","author":"Aqsa","year":"2021","journal-title":"Case Rep. Gastroenterol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.3390\/ijms20194712","article-title":"Drug-induced hypertension caused by multikinase inhibitors (sorafenib, sunitinib, lenvatinib and axitinib) in renal cell carcinoma treatment","volume":"20","author":"B\u00e6k M\u00f8ller","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.3390\/cancers15061851","article-title":"Neuropsychiatric adverse drug reactions with tyrosine kinase inhibitors in gastrointestinal stromal tumors: an analysis from the European spontaneous adverse event reporting system","volume":"15","author":"Barbieri","year":"2023","journal-title":"Cancers"},{"key":"B5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1345\/aph.1M469","article-title":"Bronchial fistula associated with sunitinib in a patient previously treated with radiation therapy","volume":"44","author":"Basille","year":"2010","journal-title":"Ann. Pharmacother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1093\/annonc\/mds003","article-title":"A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy","volume":"23","author":"Baumann","year":"2012","journal-title":"Ann. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMc0802736","article-title":"Scrotal cutaneous side effects of sunitinib","volume":"359","author":"Billemont","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.eururo.2022.08.019","article-title":"Epidemiology of renal cell carcinoma: 2022 update","volume":"82","author":"Bukavina","year":"2022","journal-title":"Eur. Urol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.gastrohep.2020.08.006","article-title":"Fulminant liver failure in a patient treated with Sunitinib for metastatic gastrointestinal stromal tumor","volume":"44","author":"Casas Deza","year":"2021","journal-title":"Gastroenterol. Hepatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1200\/JCO.2007.13.5145","article-title":"Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial","volume":"26","author":"Cella","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1346-8138.2012.01681.x","article-title":"Sunitinib-induced scrotal cutaneous side-effect","volume":"40","author":"Chou","year":"2013","journal-title":"J. Dermatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1200\/JCO.2012.43.3391","article-title":"Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer","volume":"31","author":"Crown","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"660","DOI":"10.7326\/0003-4819-145-9-200611070-00008","article-title":"Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors","volume":"145","author":"Desai","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e071752","DOI":"10.1136\/bmj-2022-071752","article-title":"Characterization and corroboration of safety signals identified from the US Food and drug administration adverse event reporting system, 2008-19: cross sectional study","volume":"379","author":"Dhodapkar","year":"2022","journal-title":"BMJ"},{"key":"B16","doi-asserted-by":"publisher","first-page":"4068","DOI":"10.1200\/JCO.2008.20.5476","article-title":"Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma","volume":"27","author":"Escudier","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"B17","unstructured":"SUTENT\u00ae (sunitinib malate)2021"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.1093\/annonc\/mds179","article-title":"Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib","volume":"23","author":"George","year":"2012","journal-title":"Ann. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/s10495-013-0937-0","article-title":"Mechanisms of apoptosis in irradiated and sunitinib-treated follicular thyroid cancer cells","volume":"19","author":"Grosse","year":"2014","journal-title":"Apoptosis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.ejso.2007.10.011","article-title":"Sunitinib in the management of gastrointestinal stromal tumours (GISTs)","volume":"34","author":"Hopkins","year":"2008","journal-title":"Target. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1007\/s10147-012-0497-2","article-title":"Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis","volume":"18","author":"Ibrahim","year":"2013","journal-title":"Int. J. Clin. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/S1470-2045(09)70222-0","article-title":"Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials","volume":"10","author":"Je","year":"2009","journal-title":"Lancet. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ctrv.2010.04.008","article-title":"Practical management of tyrosine kinase inhibitor-associated side effects in GIST","volume":"37","author":"Joensuu","year":"2011","journal-title":"Cancer Treat. Rev."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1200\/JCO.2017.77.1485","article-title":"Phase II study of two weeks on, one week off sunitinib scheduling in patients with metastatic renal cell carcinoma","volume":"36","author":"Jonasch","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1161\/HYPERTENSIONAHA.109.149690","article-title":"Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels","volume":"56","author":"Kappers","year":"2010","journal-title":"Hypertension"},{"key":"B26","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2165\/00002018-200730050-00001","article-title":"Guidelines for submitting adverse event reports for publication","volume":"30","author":"Kelly","year":"2007","journal-title":"Drug Saf."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1002\/hep.22272","article-title":"Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals","volume":"47","author":"Lammert","year":"2008","journal-title":"Hepatology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/ajco.12163","article-title":"Sunitinib in metastatic renal cell carcinoma: an ethnic Asian subpopulation analysis for safety and efficacy","volume":"10","author":"Lee","year":"2014","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"113439","DOI":"10.1016\/j.ejca.2023.113439","article-title":"Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: a phase 2, multicenter, randomized, open-label study in China","volume":"196","author":"Li","year":"2024","journal-title":"Eur. J. cancer (Oxford, Engl. 1990)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1290975","DOI":"10.3389\/fphar.2024.1290975","article-title":"A real-world disproportionality analysis of mesalazine data mining of the public version of FDA adverse event reporting system","volume":"15","author":"Liu","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/01.cad.0000361534.44052.c5","article-title":"Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib","volume":"21","author":"Mena","year":"2010","journal-title":"Anticancer. Drugs."},{"key":"B32","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s40261-017-0503-6","article-title":"Can disproportionality analysis of post-marketing case reports be used for comparison of drug safety profiles?","volume":"37","author":"Michel","year":"2017","journal-title":"Clin. Drug Investig."},{"key":"B33","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s11523-019-00653-5","article-title":"Sunitinib for metastatic renal cell carcinoma: a systematic review and meta-analysis of real-world and clinical trials data","volume":"14","author":"Moran","year":"2019","journal-title":"Target. Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3389\/fphar.2017.00367","article-title":"Hepatocellular toxicity associated with tyrosine kinase inhibitors: mitochondrial damage and inhibition of glycolysis","volume":"8","author":"Paech","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0140-6736(21)00152-5","article-title":"A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial","volume":"397","author":"Pal","year":"2021","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"publisher","first-page":"4610","DOI":"10.3390\/cancers14194610","article-title":"Adrenal insufficiency with anticancer tyrosine kinase inhibitors targeting vascular endothelial growth factor receptor: analysis of the FDA adverse event reporting system","volume":"14","author":"Raschi","year":"2022","journal-title":"Cancers"},{"key":"B38","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/jnci\/djr128","article-title":"Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"103","author":"Rini","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"B40","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00520-008-0409-1","article-title":"Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib","volume":"16","author":"Rosenbaum","year":"2008","journal-title":"Support. Care Cancer."},{"key":"B41","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1620\/tjem.222.39","article-title":"Sunitinib-induced thyrotoxicosis followed by persistent hypothyroidism with shrinkage of thyroid volume","volume":"222","author":"Sakurai","year":"2010","journal-title":"Tohoku. J. Exp. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1200\/JCO.2007.12.8637","article-title":"Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy","volume":"25","author":"Saltz","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1634\/theoncologist.2019-0605","article-title":"Real-world assessment of clinical outcomes among first-line sunitinib patients with clear cell metastatic renal cell carcinoma (mRCC) by the international mRCC database consortium risk group","volume":"25","author":"Savard","year":"2020","journal-title":"Oncologist"},{"key":"B45","doi-asserted-by":"publisher","first-page":"JCO2018791905","DOI":"10.1200\/JCO.2018.79.1905","article-title":"Epidemiology and risk factors for kidney cancer","volume":"36","author":"Scelo","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.euf.2017.01.006","article-title":"Variability of sex disparities in cancer incidence over 30 Years: the striking case of kidney cancer","volume":"4","author":"Scelo","year":"2018","journal-title":"Eur. Urol. Focus"},{"key":"B47","doi-asserted-by":"publisher","first-page":"5592","DOI":"10.1038\/s41598-024-56335-4","article-title":"Electrolyte disorders induced by six multikinase inhibitors therapy for renal cell carcinoma: a large-scale pharmacovigilance analysis","volume":"14","author":"She","year":"2024","journal-title":"Sci. Rep."},{"key":"B48","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/sj.bjc.6606029","article-title":"The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma","volume":"104","author":"Shinohara","year":"2011","journal-title":"Br. J. Cancer."},{"key":"B49","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"Ca. Cancer J. Clin."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1592\/phco.24.13.1099.38090","article-title":"Pharmacovigilance in the 21st century: new systematic tools for an old problem","volume":"24","author":"Szarfman","year":"2004","journal-title":"Pharmacotherapy"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1016\/S1470-2045(15)70120-8","article-title":"Sunitinib benefits patients with small-cell lung cancer","volume":"16","author":"Tanday","year":"2015","journal-title":"Lancet. Oncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1362484","DOI":"10.3389\/fphar.2024.1362484","article-title":"A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS)","volume":"15","author":"Tang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ctrv.2012.09.004","article-title":"Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis","volume":"39","author":"Teo","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"B54","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.pharmthera.2015.05.009","article-title":"Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors","volume":"152","author":"Terada","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1209933","DOI":"10.3389\/fphar.2023.1209933","article-title":"Psychiatric adverse reactions to non-selective RET multi-kinase inhibitors: a large-scale pharmacovigilance analysis","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/02841860802314720","article-title":"Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis","volume":"48","author":"Zhu","year":"2009","journal-title":"Acta. Oncol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1320458","DOI":"10.3389\/fphar.2023.1320458","article-title":"A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database","volume":"14","author":"Zou","year":"2023","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1407709\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T05:09:35Z","timestamp":1721797775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1407709\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":57,"alternative-id":["10.3389\/fphar.2024.1407709"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1407709","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,24]]},"article-number":"1407709"}}